The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Atazanavir Rowex 300 mg Capsules hard

300 milligram(s) Capsule, hard

Rowex LtdPA0711/287/004

Main Information

Trade NameAtazanavir Rowex 300 mg Capsules hard
Active SubstancesAtazanavir sulfate
Strength300 milligram(s)
Dosage FormCapsule, hard
Licence HolderRowex Ltd
Licence NumberPA0711/287/004

Group Information

ATC CodeJ05AE08 atazanavir


Licence Issued22/03/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See: Summary of Product Characteristics, section 4.2)
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back